Alvogen Pharma US, Inc. (“Alvogen”), a privately owned US-based pharmaceutical company, announces a definitive agreement by its shareholders to sell its parent company to Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE: 1795). Under the terms of the agreement, Alvogen will become a controlled subsidiary of Lotus, subject to customary closing conditions. The agreement builds upon the existing long-standing collaboration between Alvogen and Lotus including several highly successful co-developed product launches, and gives Lotus access to a U.S. platform including a dedicated salesforce, in-house manufacturing at Alvogen’s Norwich, New York facility, and a complementary R&D pipeline.
Read the full article: Alvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics Platform //
Source: https://www.prnewswire.com/news-releases/alvogen-announces-sale-to-lotus-creating-a-leading-international-specialized-generics-platform-302564869.html